I keep skin-care hopes apart from an energy claim
An ingredient does something interesting inside the body. Does adding more help? GHK-Cu and NAD+ both bring me back to that question.
They’re different substances, too. GHK-Cu is a peptide holding copper. NAD+ is a coenzyme, a helper in the cell’s chemical reactions. It isn’t a peptide, even if it often turns up in the same conversation.
Skin is the question for GHK-Cu
GHK-Cu is a chain of three amino acids, the building blocks of proteins, holding copper. It often appears on skin-care lists as copper tripeptide-1. An early experiment in skin cells found more collagen production. One job of the protein collagen is to give skin strength.
That study was in a dish. It explains why someone might want to test a cream, but it can’t tell us what happens on a face.
A small trial after laser skin treatment couldn’t show a clear difference in redness or wrinkles between the groups with and without copper-peptide skin care. People using it did report more satisfaction. I want to keep both findings: people’s impressions matter, and a small study can leave a difference unresolved. Recently lasered skin is also a very particular setting.
Small topical studies can miss uncommon harms and don’t settle long-term safety. Injections raise a separate concern: FDA flags possible immune reactions and limited human safety information.
The injectable form of GHK-Cu appears under nominations that were withdrawn on the FDA safety page dated April 22, 2026. Requests were taken back; FDA didn’t clear it for compounding. That statement is about injections.
FDA also explains that cosmetics generally don’t need approval before sale. Claims to treat disease or change how the body works can make something a drug. An ingredient’s place in skin care doesn’t establish it as an approved medicine.
Energy is a different question for NAD+
NAD+ helps cells carry out reactions that release usable energy. That doesn’t, by itself, show that adding more gives someone a brighter afternoon.
NR, short for nicotinamide riboside, is material the body can use to make NAD+. An oral NR trial raised blood NAD+ levels. It tested a precursor, rather than an NAD+ infusion. A review of human precursor studies found limited evidence of clinical benefit, meaning improvements in people’s health.
The oral NR trial lasted eight weeks and found no significant difference in side effects from placebo. That leaves long-term safety unanswered, and it can’t establish safety for a different route. NAD+ infusions are not FDA-approved; compounding doesn’t make them approved.
I’d keep these claims small enough to check. A skin claim needs skin results. An energy claim needs more than a blood test. Persistent skin or fatigue concerns are something a licensed U.S. clinician can assess, with room to discuss established options.
Publication note: published October 27, 2026; last revised October 27, 2026. General reading, with no individual treatment advice.